Overview

A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced/metastatic solid tumors
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Henlius Biotech